Michael E. Hanson
Direktor/Vorstandsmitglied bei ActivBiotics, Inc.
Vermögen: - $ am 31.12.2021
Profil
Mr. Michael E.
Hanson is Industry Expert at Pearl Street Venture Funds.
Previously he was with Eli Lilly and Company where he was President of the Internal Medicine Business Unit and served on the Operations Committee.
He is currently on the board of a number of early-stage life science companies including GlycoGenesis, Sound Technologies, Inc., Z-29, Inc., and was a past board member of MGI Pharma.
Mr. Hanson has a BS in Pharmacy from North Dakota State University, Fargo, a MS in Hospital Pharmacy Administration, University of Minnesota, Minneapolis and attended the Advanced Management Program at Harvard Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NEWCARDIO INC PFCV SER D
1,00% | 21.03.2011 | 10 ( 1,00% ) | 0 $ | 31.12.2021 |
Aktive Positionen von Michael E. Hanson
| Unternehmen | Position | Beginn |
|---|---|---|
ActivBiotics, Inc.
 ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | Direktor/Vorstandsmitglied | - |
| Barnard Life Sciences LLC | Corporate Officer/Principal | 01.01.2001 |
| Z-92 Pharma | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Michael E. Hanson
| Unternehmen | Position | Ende |
|---|---|---|
Indevus Pharmaceuticals, Inc.
 Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Direktor/Vorstandsmitglied | 23.02.2009 |
| WILLIAMS INDUSTRIAL SERVICES GROUP INC. | Finanzdirektor/CFO | 01.02.2008 |
Glycogenesys, Inc.
 Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | 01.01.2006 |
MGI PHARMA, Inc.
 MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | Direktor/Vorstandsmitglied | 01.01.2001 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.01.1997 |
Ausbildung von Michael E. Hanson
| North Dakota State University | Undergraduate Degree |
| University of Minnesota | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| WILLIAMS INDUSTRIAL SERVICES GROUP INC. | Industrial Services |
| NEWCARDIO, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | Health Technology |
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Commercial Services |
Eleos, Inc.
 Eleos, Inc. Medical SpecialtiesHealth Technology Eleos, Inc. developed therapeutic and cancer treatments services. The company was founded by Larry J. Smith in 2001 and was headquartered in Omaha, NE. | Health Technology |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | Health Technology |
Lilly Research Laboratories
 Lilly Research Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Research Laboratories is a company that engages in research and develops medicines. The company is based in Indianapolis, IN. | Commercial Services |
| Barnard Life Sciences LLC | |
Eli Lilly Japan KK
 Eli Lilly Japan KK Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Japan KK is a Japanese company that manufactures and trades pharmaceutical products. The company is based in Kobe, Japan. | Health Technology |
| Z-92 Pharma |
